疟疾疫苗实施项目中引入和交付RTS,S/AS01疟疾疫苗的成本
研究从政府视角对加纳、肯尼亚和马拉维试点引入RTS,S/AS01疟疾疫苗进行回顾性成本分析,估算常规免疫规划下引入和交付的增量成本。疫苗价格5美元/剂时,每剂增量经济成本8.28–10.29美元,财务成本2.30–3.01美元;引入成本占财务总成本33%–71%。
要点
- 疫苗价格5美元/剂时,各国每剂增量经济成本8.28–10.29美元,财务成本2.30–3.01美元。
- 非疫苗交付成本(经济)每剂1.52–4.62美元,引入成本占财务总成本33%–71%。
- 商品和采购附加成本是各国总成本的主要驱动因素。
核心结论
- 引入RTS,S的财务成本与其他新疫苗引入成本相当,各国资源需求主要受疫苗价格和潜在捐赠资金影响。
研究设计与样本
- 基于活动的回顾性成本核算,从政府视角开展,成本数据来自2019–2021年试点项目支出和活动报告,并收集代表性卫生机构原始数据。
- 成本分为引入成本和经常性成本,估算财务成本和经济成本,以2020年美元报告。
- 捐赠疫苗剂量成本按每剂2美元、5美元和10美元评估并纳入经济成本估算。
主要发现
- 疫苗价格5美元/剂时,各国每剂增量成本:财务成本2.30–3.01美元,经济成本8.28–10.29美元。
- 非疫苗交付成本:财务成本每剂1.04–2.46美元,经济成本每剂1.52–4.62美元,各国不同。
- 仅考虑经常性成本时,非疫苗交付成本:财务成本每剂0.29–0.89美元,经济成本每剂0.59–2.29美元,各国不同。
- 引入成本占财务总成本的33%–71%。
- 商品和采购附加成本是各国总成本的主要驱动因素。
关键数值与推荐
- 疫苗价格5美元/剂时,每剂增量财务成本2.30–3.01美元,经济成本8.28–10.29美元。
- 非疫苗交付成本(财务)每剂1.04–2.46美元,经济成本每剂1.52–4.62美元。
- 仅经常性成本的非疫苗交付成本(财务)每剂0.29–0.89美元,经济成本每剂0.59–2.29美元。
- 引入成本占财务总成本33%–71%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) recommended widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children residing in regions of moderate to high malaria transmission. This recommendation is informed by RTS,S evidence, including findings from the pilot rollout of the vaccine in Ghana, Kenya, and Malawi. This study estimates the incremental costs of introducing and delivering the malaria vaccine within routine immunization programs in the context of malaria vaccine pilot introduction, to help inform decision-making. METHODS: An activity-based, retrospective costing was conducted from the governments' perspective. Vaccine introduction and delivery costs supported by the donors during the pilot introduction were attributed as costs to the governments under routine implementation. Detailed resource use data were extracted from the pilot program expenditure and activity reports for 2019-2021. Primary data from representative health facilities were collected to inform recurrent operational and service delivery costs.Costs were categorized as introduction or recurrent costs. Both financial and economic costs were estimated and reported in 2020 USD. The cost of donated vaccine doses was evaluated at $2, $5 and $10 per dose and included in the economic cost estimates. Financial costs include the procurement add on costs for the donated vaccines and immunization supplies, along with other direct expenses. FINDINGS: At a vaccine price of $5 per dose, the incremental cost per dose administered across countries ranges from $2.30 to $3.01 (financial), and $8.28 to $10.29 (economic). The non-vaccine cost of delivery ranges between $1.04 and $2.46 (financial) and $1.52 and $4.62 (economic), by country. Considering only recurrent costs, the non-vaccine cost of delivery per dose ranges between $0.29 and $0.89 (financial) and $0.59 and $2.29 (economic), by country. Introduction costs constitute between 33% and 71% of total financial costs. Commodity and procurement add-on costs are the main cost drivers of total cost across countries. Incremental resource needs for implementation are dependent on country's baseline immunization program capacity constraints. INTERPRETATION: The financial costs of introducing RTS,S are comparable with costs of introducing other new vaccines. Country resource requirements for malaria vaccine introduction are most influenced by vaccine price and potential donor funding for vaccine purchases and introduction support.
引用
- Baral R, Levin A, Odero C, et al. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program. Vaccine. 2023. PMID: 36710234. doi:10.1016/j.vaccine.2023.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。